Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis
Oliver, D.; Chesney, E.; Wallman, P.; Estrade, A.; Azis, M.; Provenzani, U.; Damiani, S.; Melillo, A.; Hunt, O.; Agarwala, S.; Minichino, A.; Uhlhaas, P. J.; McGuire, P.; Fusar-Poli, P.
Show abstract
BackgroundAt present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We sought to assess the acceptability of cannabidiol (CBD): a promising candidate treatment for this population. MethodsCHR-P individuals completed a survey which assessed their views on the acceptability of CBD, its expected effectiveness and side effects, and on formulation preferences. ResultsThe sample comprised 55 CHR-P individuals (24.3 years and 69% female). Most (91%) were familiar with CBD, and had previously used cannabis (64%), and around half (42%) had tried over-the-counter CBD. 75% were willing to take CBD as an intervention for mental health problems. Most participants anticipated fewer side effects with CBD than with existing medications, and preferred tablet or capsule formulations over liquids. DiscussionCBD is perceived as a highly acceptable treatment among CHR-P individuals.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.